Understand the source comparison
Comparison: Hexarelin Fat Loss Results Timeline vs Other GH Secretagogues
Hexarelin GHS-R1a agonist (selective) 4–6 weeks (VAT), 10–12 weeks (SAT) 6–10× baseline Minimal at doses ≤400mcg/day Fastest visceral fat mobilization among GH secretagogues, minimal ghrelin-driven appetite increase makes it ideal for fat loss protocols Ipamor
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hexarelin
- GHS-R1a agonist (selective)
- 4–6 weeks (VAT), 10–12 weeks (SAT)
- 6–10× baseline
- Minimal at doses ≤400mcg/day
- Fastest visceral fat mobilization among GH secretagogues, minimal ghrelin-driven appetite increase makes it ideal for fat loss protocols
- Ipamorelin
- GHS-R1a agonist (highly selective)
- 6–8 weeks (VAT), 12–14 weeks (SAT)
- 3–5× baseline
- Slowest timeline but cleanest side effect profile. No cortisol or prolactin elevation, suitable for longer protocols
- GHRP-6
- Ghrelin receptor agonist (non-selective)
- 8–10 weeks (combined VAT/SAT)
- 8–12× baseline
- Significant (hunger spikes 30–60 min post-dose)
- Strong GH response but appetite stimulation counteracts fat loss. Requires strict dietary control
- MK 677 (Ibutamoren)
- Oral GHS-R1a agonist
- 10–14 weeks (combined VAT/SAT)
- 4–6× baseline sustained 24h
- Moderate to significant
- Oral convenience with sustained GH elevation, but water retention and appetite increase complicate fat loss interpretation
- CJC-1295 + Ipamorelin
- GHRH analog + GHS-R1a agonist (combination)
- 6–10 weeks (VAT), 12–16 weeks (SAT)
- 5–8× baseline (synergistic)
- Synergistic GH pulse amplitude and frequency increase. Effective but requires twice-daily dosing for optimal results